We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+19.19%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$783M
AUM Growth
+$36.9M
Cap. Flow
-$49.7M
Cap. Flow %
-6.35%
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
13

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$22.4M
2
KROS icon
Keros Therapeutics
KROS
+$11M
3
SYK icon
Stryker
SYK
+$9.66M
4
RCUS icon
Arcus Biosciences
RCUS
+$9.62M
5
DGX icon
Quest Diagnostics
DGX
+$8.21M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$16M
2
ELV icon
Elevance Health
ELV
+$15M
3
HUM icon
Humana
HUM
+$11.2M
4
COR icon
Cencora
COR
+$8.56M
5
THC icon
Tenet Healthcare
THC
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
26
Bicycle Therapeutics
BCYC
$284M
$10.1M 1.29%
445,396
-89,667
-17% -$2.07M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.76B
$9.86M 1.26%
438,971
-35,708
-8% -$809K
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.77B
$9.78M 1.25%
508,283
-92,415
-15% -$1.91M
VRDN icon
29
Viridian Therapeutics
VRDN
$2.59B
$9.67M 1.23%
+425,000
New +$6.95M
QGEN icon
30
Qiagen
QGEN
$8.88B
$9.6M 1.23%
204,914
-22,846
-10% -$1.04M
RXST icon
31
RxSight
RXST
$294M
$9.11M 1.16%
184,320
-112,419
-38% -$5.76M
SLN
32
Silence Therapeutics
SLN
$641M
$9.05M 1.16%
497,870
+208,029
+72% +$3.87M
DGX icon
33
Quest Diagnostics
DGX
$26.2B
$8.54M 1.09%
+55,000
New +$8.21M
CSTL icon
34
Castle Biosciences
CSTL
$960M
$8.44M 1.08%
296,071
+18,176
+7% +$463K
REPL icon
35
Replimune Group
REPL
$1.28B
$8.37M 1.07%
763,747
+238,747
+45% +$2.43M
CDMO
36
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$8.19M 1.05%
719,965
+98,874
+16% +$992K
JAZZ icon
37
Jazz Pharmaceuticals
JAZZ
$16.2B
$8.05M 1.03%
+72,256
New +$7.92M
APLT
38
DELISTED
Applied Therapeutics
APLT
$7.71M 0.98%
907,294
-241,013
-21% -$1.42M
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.31B
$7.55M 0.96%
191,658
-17,632
-8% -$711K
ICLR icon
40
Icon
ICLR
$12.9B
$7.53M 0.96%
26,212
-10,844
-29% -$3.42M
PTCT icon
41
PTC Therapeutics
PTCT
$6.06B
$7.23M 0.92%
+195,000
New +$6.53M
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$30B
$7.01M 0.89%
+25,485
New +$6.64M
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$6.46M 0.83%
605,318
+102,855
+20% +$1.12M
RARE icon
44
Ultragenyx Pharmaceutical
RARE
$2.65B
$6.08M 0.78%
109,468
+9,468
+9% +$482K
CVRX icon
45
CVRx
CVRX
$72.7M
$6.02M 0.77%
682,897
+235,277
+53% +$2.14M
STRO icon
46
Sutro Biopharma
STRO
$353M
$5.94M 0.76%
171,613
-7,661
-4% -$300K
AXGN icon
47
Axogen
AXGN
$2.67B
$5.79M 0.74%
+412,888
New +$4.57M
ACLX
48
DELISTED
Arcellx
ACLX
$5.55M 0.71%
66,492
-90,351
-58% -$6.02M
PHLT
49
DELISTED
Performant Healthcare Inc
PHLT
$5.39M 0.69%
1,440,838
-182,361
-11% -$623K
LIVN icon
50
LivaNova
LIVN
$4.45B
$5.34M 0.68%
101,729
+16,570
+19% +$821K
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Parkman Healthcare Partners held 106 positions worth $783M, up 4.9% from $747M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $49.7M in Q3 2024, closing 13 positions and reducing 39 holdings. Its most notable exit was Elevance Health, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Teleflex worth $23.8M.

  • Parkman Healthcare Partners's largest Q3 2024 buy was Teleflex: 96,144 shares worth $23.8M.
  • Parkman Healthcare Partners added most to Keros Therapeutics in Q3 2024, an estimated $11M increase.
  • Parkman Healthcare Partners's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $16M.
  • Parkman Healthcare Partners fully exited Elevance Health in Q3 2024, selling an estimated $15M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $783M portfolio in Q3 2024.
  • Parkman Healthcare Partners opened 16 new positions and closed 13 in Q3 2024.
  • Parkman Healthcare Partners's portfolio value rose 4.9% quarter-over-quarter to $783M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.